China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with domestic firm Glyco-Therapy. This collaboration aims to create a comprehensive resource cooperation and service platform for the development of next-generation antibody drug conjugates (ADCs).
Innovative Approach to ADC Development
The partnership will focus on the entire lifecycle of ADCs, from early drug discovery through clinical pharmaceutical research to commercial production. By leveraging their combined expertise, ZhenGe Biotech and Glyco-Therapy seek to establish a diversified and efficient platform that enhances the development process of ADCs. Specific financial details of the partnership have not been disclosed.
Glyco-Therapy’s Technological Edge
Founded in 2019 in Hangzhou, Glyco-Therapy is recognized for its innovative YTConju technology platform, which specializes in fucosyl conjugates. This technology is expected to play a pivotal role in the development of high-quality ADCs, further strengthening the capabilities of both companies in the biopharmaceutical landscape.-Fineline Info & Tech
